Cytogen Corp. has provided Endotronics Inc.'s first commercial biotechnology contractfor several trial batches of monoclonal antibodies for use in clinical programs,Endotronics said.

Endotronics (NASDAQ:ENDO), a cell culture production-scale instrument company based inMinneapolis, also announced it has filed a type I drug master file with FDA that describedthe procedures, equipment and facilities it has to offer contract manufacture of clinicalgrade biopharmaceuticals. This filing is one step the company has taken to upgrade itscontract production services of monoclonal antibodies for human injectable products,including in vivo diagnostics and therapeutics.

No Comments